XO1 Limited

Overview

Legal name

XO1 LIMITED

Region

South East England

Registered address

Unknown

Insolvency history

Corporate ownership

Updated 06 Jun 2026 16:52

1 level 1 ultimate controller

Company Active LTD

XO1 Limited

CRN 08424622

Direct and ultimate controller

NOT APPLICABLE

CRN NOT APPLICABLE

Company events

Reference milestones and recent Companies House filing stream events.

7 events

08 Oct

2024

Appoint Person Secretary Company With Name Date

Officers

AP03 | Transaction MzQzODcxNTE1MGFkaXF6a2N4

Published 08 Oct 2024 10:21

08 Oct

2024

Termination Secretary Company With Name Termination Date

Officers

TM02 | Transaction MzQzODcxNTE4OGFkaXF6a2N4

Published 08 Oct 2024 10:21

01 Oct

2024

Legacy

Insolvency

CAP-SS | Transaction MzQzNzkyNTcyM2FkaXF6a2N4 | Paper/PDF filed

Published 03 Oct 2024 06:56

01 Oct

2024

Resolution

RESOLUTIONS | Transaction WURDVTlOUVJhZGlxemtjeA | Paper/PDF filed

Published 03 Oct 2024 06:49

01 Oct

2024

Capital Statement Capital Company With Date Currency Figure

Capital

SH19 | Transaction MzQzNzkyNjIwOGFkaXF6a2N4 | Paper/PDF filed

Published 02 Oct 2024 06:23

01 Oct

2024

Legacy

Capital

SH20 | Transaction MzQzNzkyNTg4MWFkaXF6a2N4 | Paper/PDF filed

Published 02 Oct 2024 06:18

28 Feb

2013

Incorporated

Inception

Company registered at Companies House

Public funding

1 award

First funded

2014

Funded years

2014

Age at first award

1 years

Projects

2014 Collaborative R&D Lead participant

Evaluation of an antibody that inhibits thrombosis without causing bleeding

1 Oct 2014 to 30 Sep 2016

Awarded

£1,103,209

Total cost £1,838,682

Thrombosis remains a major cause of death and morbidity worldwide. Existing antithrombotics reduce clotting but also increase bleeding, limiting their use. No agents approved for marketing or in clinical trials have been shown to significantly dissociate this bleeding risk from the degree of antithrombosis. This project relates to the initial manufacture ...

Product types

Collaborative R&D